{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:37:40Z","timestamp":1790689060449,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012752","name":"Elanco Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ilunocitinib is a new molecular entity of the Janus kinase inhibitor (JAKi) class for the treatment and control of symptoms of allergic skin disease conditions, such as pruritus and skin lesions in dogs. This laboratory study with ilunocitinib tablets (Zenrelia\u2122, Elanco) investigated the safety in healthy dogs treated once daily for 6 months. The study was a randomized, blinded, parallel-group design examining one (1X), two (2X), three (3X) and five (5X) times the maximum recommended dose (0.8\u00a0mg\/kg) compared to sham dosed control dogs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty male and 20 female healthy Beagle dogs, 11 to 12-month of age, with a mean body weight ranging from 9.85 to 10.46\u00a0kg, were randomized to an untreated control group or ilunocitinib treatment groups at daily dose rates of 0.8\u00a0mg\/kg (1X), 1.6\u00a0mg\/kg (2X), 2.4\u00a0mg\/kg (3X), or 4.0\u00a0mg\/kg (5X) over six months. All animals were fed within 30\u00a0min prior to treatment. Safety assessments included general health observations, clinical observations (including complete physical and neurological examinations), ophthalmology, clinical pathology, peripheral blood immunophenotyping, body weight, food consumption, pharmacokinetic blood collections, organ macroscopic and microscopic examinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No effects of the treatment were noted on body weight, food consumption, physical and neurological examinations, urinalysis, peripheral blood immunophenotype, and ophthalmoscopic examinations. Clinical findings included non-exudative skin lesions, skin lesions with discharge, swollen paw(s), skin thickening, skin discoloration or scabbing of the feet (paws\/digits), in both male and female dogs. Changes in clinical pathology included marginally decreased red cell mass, lower eosinophils, higher C-reactive protein, total protein and fibrinogen, lower albumin and albumin: globulin levels. Microscopic findings included skin inflammation and focal dermatitis\/furunculosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Ilunocitinib was well tolerated when administered daily over six months at 0.8\u00a0mg\/kg and multiples thereof up to 4.0\u00a0mg\/kg in Beagle dogs. At the therapeutic dose, no clinically significant changes were observed. Minimal changes in hematological parameters, total protein, and fibrinogen were noted at the higher doses. All of these findings, consistent with the known pharmacology of the JAKi class at exaggerated dosing, support the safe and chronic use of Zenrelia\u2122 tablets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12917-025-04579-1","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:53:26Z","timestamp":1741157606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of ilunocitinib tablets (Zenrelia\u2122) after once daily oral administration in dogs"],"prefix":"10.1186","volume":"21","author":[{"given":"Emmanuelle A.","family":"Kuntz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Gabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line E.","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"4579_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00899.x","author":"M Linek","year":"2010","unstructured":"Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol. 2010. https:\/\/doi.org\/10.1111\/j.1365-3164.2010.00899.x","journal-title":"Vet Dermatol"},{"key":"4579_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12801","author":"C Favrot","year":"2020","unstructured":"Favrot C, Fischer N, Olivry T, Zwickl L, Audergon S, Rostaher A. Atopic dermatitis in West Highland white terriers \u2013 part I: natural history of atopic dermatitis in the first three years of life. Vet Dermatol. 2020. https:\/\/doi.org\/10.1111\/vde.12801","journal-title":"Vet Dermatol"},{"key":"4579_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/9780470752487","volume-title":"Skin diseases of the dog and cat: clinical and histopathologic diagnosis","author":"T Gross","year":"2005","unstructured":"Gross T, Ihrke PJ, Walder EJ, Affolter V. Skin diseases of the dog and cat: clinical and histopathologic diagnosis. Oxford: Blackwell Science; 2005. https:\/\/doi.org\/10.1002\/9780470752487"},{"key":"4579_CR4","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014. https:\/\/doi.org\/10.1021\/jm401490p","journal-title":"J Med Chem"},{"key":"4579_CR5","doi-asserted-by":"publisher","DOI":"10.2147\/VMRR.S412570","author":"Y Drechsler","year":"2024","unstructured":"Drechsler Y, Dong C, Clark DE, Kaur G. Canine atopic dermatitis: prevalence, impact, and management strategies. Vet Med (Auckl). 2024. https:\/\/doi.org\/10.2147\/VMRR.S412570","journal-title":"Vet Med (Auckl)"},{"key":"4579_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00333-w","author":"AT Virtanen","year":"2019","unstructured":"Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019. https:\/\/doi.org\/10.1007\/s40259-019-00333-w","journal-title":"BioDrugs"},{"key":"4579_CR7","unstructured":"Forster S, Trout C, Despa S, Boegel A, Berger D, King S. Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: a multicenter, masked, randomized, placebo-controlled clinical trial. Manuscript in preparation."},{"key":"4579_CR8","unstructured":"Forster S, Trout C, Despa S, Boegel A, Berger D, King S. Efficacy and field safety of ilunocitinib for the control of allergic dermatitis in client-owned dogs: a multicenter, double-masked, randomized, placebo-controlled clinical trial. Manuscript in preparation."},{"key":"4579_CR9","unstructured":"Forster S, Despa S, Trout C, King S. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Manuscript submitted for publication."},{"key":"4579_CR10","unstructured":"Veterinary International Conference on Harmonization (VICH). Guideline 43: Target Animal Safety for Veterinary Pharmaceutical Products. 2009. https:\/\/www.vichsec.org\/en\/guidelines\/pharmaceuticals\/pharma-safety\/pharma-target-animal-safety.html. Accessed 29 Jul 2024."},{"key":"4579_CR11","unstructured":"United States Food and Drug Administration. Code of Federal Regulations Title 21, Part 58, Good Laboratory Practice for nonclinical laboratory studies. 2016. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-58. Accessed 29 Jul 2024."},{"key":"4579_CR12","doi-asserted-by":"publisher","unstructured":"Organisation for Economic Cooperation and Development (OECD). Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring. 1997. https:\/\/www.oecd-ilibrary.org\/environment\/oecd-series-on-principles-of-good-laboratory-practice-and-compliance-monitoring_2077785x. https:\/\/doi.org\/10.1787\/2077785x. Accessed 29 Jul 2024.","DOI":"10.1787\/2077785x"},{"key":"4579_CR13","unstructured":"Animal and Plant Health Inspection Service, Department of Agriculture. Code of Federal Regulations. 9 CFR Chapter I Subchapter. https:\/\/www.ecfr.gov\/current\/title-9\/chapter-I\/subchapter-A. Accessed on 29 Jul 2024."},{"key":"4579_CR14","doi-asserted-by":"publisher","DOI":"10.17226\/5140","volume-title":"Guide for the Care and Use of Laboratory animals","author":"National Research Council","year":"1996","unstructured":"National Research Council. Guide for the Care and Use of Laboratory animals. Washington, DC: National Academies; 1996. https:\/\/doi.org\/10.17226\/5140. Accessed on 29 Jul 2024."},{"key":"4579_CR15","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.72351","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother. 2010. https:\/\/doi.org\/10.4103\/0976-500X.72351","journal-title":"J Pharmacol Pharmacother"},{"key":"4579_CR16","unstructured":"Food and Drug Administration. Guidance for industry. Bioanalytical method validation. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed on 29 Jul 2024."},{"key":"4579_CR17","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. EMEA\/CHMP\/EWP\/192217\/2009, 2011 Rev. 1 Corr. 2** superseded by the ICH guideline M10 on bioanalytical method validation and study sample analysis. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed on 29 Jul 2024."},{"key":"4579_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088","author":"SB Cosgrove","year":"2013","unstructured":"Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013. https:\/\/doi.org\/10.1111\/vde.12088","journal-title":"Vet Dermatol"},{"key":"4579_CR19","unstructured":"Food and Drug Administration. Freedom of Information Summary: Original New Animal Drug Application NADA 141\u2013585 (Zenrelia\u2122 (ilunocitinib tablets)). https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/15865"},{"key":"4579_CR20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.670331","author":"J Mishra","year":"2015","unstructured":"Mishra J, Verma RK, Alpini G, Meng F, Kumar N. Role of Janus Kinase 3 in predisposition to obesity-associated metabolic syndrome. J Biol Chem. 2015. https:\/\/doi.org\/10.1074\/jbc.M115.670331","journal-title":"J Biol Chem"},{"key":"4579_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101009","author":"D Collotta","year":"2020","unstructured":"Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Ferreira Alves G, Gaudioso G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiemermann C, Collino M. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. Mol Metabolism. 2020. https:\/\/doi.org\/10.1016\/j.molmet.2020.101009","journal-title":"Mol Metabolism"},{"key":"4579_CR22","first-page":"17","volume":"44","author":"MS Kovacs","year":"2005","unstructured":"Kovacs MS, McKiernan S, Potter DM, Chilappagari. An epidemiological study of interdigital cysts in a research Beagle colony. Contemp Top Lab Anim Sci. 2005;44:17\u201321.","journal-title":"Contemp Top Lab Anim Sci"},{"key":"4579_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/laban0507-18","author":"Diagnosis","year":"2007","unstructured":"Diagnosis. Interdigital cyst. Lab Anim. 2007. https:\/\/doi.org\/10.1038\/laban0507-18","journal-title":"Lab Anim"},{"key":"4579_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194","author":"SB Cosgrove","year":"2015","unstructured":"Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015. https:\/\/doi.org\/10.1111\/vde.12194","journal-title":"Vet Dermatol"},{"key":"4579_CR25","unstructured":"Food and Drug Administration. Freedom of Information Summary: Original New Animal Drug Application NADA 141\u2013345 (Apoquel (Oclacitinib Tablet)). https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/902. Accessed 29 Jul 2024."},{"key":"4579_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001370","author":"J Kay","year":"2020","unstructured":"Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, et al. Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001370","journal-title":"RMD Open"},{"key":"4579_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215764","journal-title":"Ann Rheum Dis"},{"key":"4579_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.03.002","author":"KJ Weinhold","year":"2018","unstructured":"Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol. 2018. https:\/\/doi.org\/10.1016\/j.clim.2018.03.002","journal-title":"Clin Immunol"},{"key":"4579_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/art.40680","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, et al. Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheumatol. 2018. https:\/\/doi.org\/10.1002\/art.40680","journal-title":"Arthritis Rheumatol"},{"key":"4579_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1245535","author":"D Collotta","year":"2023","unstructured":"Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1245535","journal-title":"Front Pharmacol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-025-04579-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:54:43Z","timestamp":1751849683000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-025-04579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4579"],"URL":"https:\/\/doi.org\/10.1186\/s12917-025-04579-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was based on the guidelines for evaluating the target animal safety of new pharmaceuticals (VICH Guideline 43), and recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58 and the Organization for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice and Compliance Monitoring, Number 13). The study was conducted at an AAALAC accredited facility and approved by their Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}